Dr Andrew John Sutton BSc. MSc. PhD

PhD Biological Sciences, University Warwick, 2007 

MSc Modern Applicable Mathematics, Sheffield Hallam University, 2001 

Postgraduate Certificate in Education, Secondary Mathematics, 11-16, Sheffield Hallam University, 2000 

BSc Open Degree, Open University, 1999

Andrew is a Senior Research Fellow who specializes in health technology assessment, reimbursement, and submission consulting for drugs, medical devices, cell therapies, and hospital technologies. He primarily collaborates with biotechs and pharmaceutical companies trying to identify and demonstrate the economic value of new innovations. He supports companies during the commercialization process to secure reimbursements from public or private payers.

Following a career in academia, in 2018 Andrew moved to Canada to work for the Institute of Health Economics (IHE) in Edmonton in the IHE Industry Partnerships - Life Sciences SME Platform supporting life sciences innovators and companies with early-stage health technology assessments to guide product development and inform early investment and commercialization decisions, as well as provide support for market-ready companies to trial and model their economic value proposition in the interests of procurement and potential adoption. He subsequently served as an Associate Director in Economic Modelling and Comparative Effectiveness at Cytel.

Andrew has a research interest in generating innovative approaches to support innovators and investors in making development and investment decisions. It is necessary for innovators to understand the potential value of their technology at an early stage, so that they can assess whether there is value in conducting further research and development. Likewise, investors need to understand how best to allocate their investment pounds to maximize the possibility that their investments will be successful. All of which helps to smooth the development pathway and helps patients access new innovations sooner.

Andrew holds a Doctorate in Biological Sciences in the mathematical modelling of infectious diseases from the University of Warwick, UK, and an MSc in Modern Applicable Mathematics from Sheffield Hallam University.

Andrew has previously taught on the MSc Health Economics and Health Policy course helping to supervise the health economic modelling module. As part of this course, Andrew has supervised multiple MSc dissertations.

Andrew has previously supervised two PhD projects to completion. These have focused on guidelines for the implementation of cost-effectiveness analysis, and the early economic evaluation of tests at their early stages of development with particular focus on typhoid testing in Ghana.

Andrew has a particular interest in evaluating health technologies at their early stages of development, with a view to supporting innovators on their development journey towards investment and adoption. Andrew would like to supervise PhD projects that are focused on developing methods that can support this area of research.

Andrew is a member of the multidisciplinary technology appraisal review (TAR) project team. Which conducts appraisals of single technology assessments submitted to the NIHR many diseases/conditions, but mainly cancers and multiple sclerosis. These appraisals aid in the decision-making process regarding the reimbursement of technologies, efficient use of scarce healthcare resources and the access to innovative treatments that lead to improved health outcomes. 

While working at the University of Leeds from 2016-2018 Andrew was a member of Diagnostic Evidence Cooperative (DEC). Working within the testing and evaluation group of the health economics unit, Andrew would support companies through the DEC providing them with early cost-effectiveness analysis to provide insights into potential pricing of the new technology, and to support them with gaining investment and adoption. 

This is Andrew’s second spell at the University of Birmingham having spent 5 years in the Health Economics Unit from 2010-2015 before moving to the University of Leeds. During this time Andrew was a co-applicant on multiple NIHR HTA submissions supporting them with model-based and trial-based cost-effectiveness analysis.